Obesity and weight loss in certain heart failure patients
Part of Heart & circulation, Hormones & metabolism clinical trials.
This study looks at how higher body weight and weight loss affect people who have heart failure with preserved pumping strength. It uses heart scans to measure how the heart and body change, which may help guide future treatment plans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have heart failure where the heart pumps with preserved strength (HFpEF)
- Your heart’s pumping measurement is more than 50% (LVEF > 50%)
- Your body mass index (BMI) is about 27.5 or higher
- You can safely have an MRI heart scan (no MRI contraindications)
- You are not pregnant, planning pregnancy, or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how obesity and weight loss affect people living with heart failure where the heart pumping strength is reduced. It uses heart imaging (MRI) to measure the heart and may help clarify what weight changes do for symptoms and heart function.
This study looks at how being overweight affects heart health. It tests a program that includes monthly check-ins and surveys, and is for people with a BMI of 30 or higher who also have a heart condition. The goal is to learn more about how to help people with both weight and heart concerns.
This study tests whether a new medication called NNC0487-0111 can help people with heart failure who also have obesity. Researchers will compare it to a placebo (inactive pill) to see if it improves heart function and overall health.
This study tests a new medicine called IBI362 for people with heart failure and obesity. The medicine may help improve symptoms and quality of life. You must have a specific type of heart failure (HFpEF or HFmrEF) and a BMI of 28 or higher.
This trial tests if weight loss surgery can help people with heart failure and atrial fibrillation (an irregular heartbeat) improve their heart condition. You may join if you are between 45 and 70, have a BMI of 32 to 40, and have mild to moderate heart failure with preserved pumping function.
This study is testing whether a new class of medications, known as GLP-1/GIP receptor agonists, can help improve symptoms and heart health in people who have heart failure with preserved ejection fraction and are overweight or obese. It is a registry that tracks participants' health over time to learn about the treatment's effects.
Hear when a new Heart Failure With Preserved Ejection Fraction trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.